The impact of anticancer drugs on the ocular surface

Chiang, Jeremy Chung Bo; Zahari, Ilyanoon; Markoulli, Maria; Krishnan, Arun V.; Park, Susanna B.; Semmler, A; Goldstein, David; Edwards, Katie

doi:10.1016/j.jtos.2020.03.008

Cited by 16 publications

(6 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ocular surface epithelia undergo constant turnover and are susceptible to cytotoxicity from numerous chemotherapeutic agents and targeted therapies used before HSCT. 34 Previous studies demonstrated that dry eye disease is already present in a significant percentage of patients before transplantation. [35][36][37] In accordance with this, 36% of patients in the present cohort had dry eye disease before transplantation.…”

Section: Discussionmentioning

confidence: 99%

Incidence, Risk Factors and Complications of Ocular Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation

Pellegrini

Bernabei

Barbato

et al. 2021

American Journal of Ophthalmology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Incidence, Risk Factors and Complications of Ocular Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation

Pellegrini

Bernabei

Barbato

et al. 2021

American Journal of Ophthalmology

View full text Add to dashboard Cite

“…Although estrogen receptors are more readily associated with reproductive organs, they are also known to be present in the cornea, lens, retina, meibomian glands, and the lacrimal glands [7][8][9][10][11]. Several studies have reported on adverse ocular effects of AIs [12][13][14]. Inglis et al [4] used the Ocular Surface Disease Index questionnaire and found a significantly higher rate of self-reported dry eye disease in patients taking AIs compared to controls.…”

Section: Discussionmentioning

confidence: 99%

“…And, while retinal and optic nerve toxicities are known adverse effects of paclitaxel, we are not aware of corneal toxicity as a reported side effect [ 23 – 27 ]. Herceptin and related drugs, however, have been associated with adverse effects on the anterior segment with dry eye, epiphora, blurred vision, and conjunctivitis being the most common [ 12 , 28 , 29 ]. It is not surprising that these drugs might have an effect on the ocular surface given the expression of HER receptors by the corneal, limbal, and conjunctival epithelia [ 30 ] and the role of HER family tyrosine kinase receptors on cell differentiation, proliferation, and migration [ 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Subepithelial Corneal Deposits Associated with Exemestane

Amireskandari

Nguyen

Hinkle

et al. 2020

Case Reports in Ophthalmological Medicine

View full text Add to dashboard Cite

This is a case report of corneal deposits noted in a 69-year-old female patient taking the aromatase inhibitor, exemestane, after undergoing a mastectomy and chemotherapy for breast cancer. The patient presented to our eye clinic for a new-onset floater in one eye, and bilateral subepithelial opacities were found incidentally on exam. The patient completed a 5-year course of the medication shortly after her initial visit with us and was noted to have a slight improvement in the density of the opacities on a follow-up visit 3 months later. We believe these corneal changes were most likely secondary to exemestane. The effect of aromatase inhibitors on the eye deserves further exploration as an increasing number of patients are prescribed these medications.

show abstract

“…Lastly, traditional chemotherapy such as alkylating agents, antimetabolites, and mitotic inhibitors have been associated with non-infectious bulbar conjunctivitis. This is presumed secondary to exposure of the conjunctival mucosal tissue to a toxic concentration of the drug within the tear film; this subsides with discontinuation of the drug (180). The lacrimal drainage system can be susceptible to these agents leading to inflammation and subsequent stenosis.…”

Section: Ocular Manifestations Secondary To Therapeutic Agentsmentioning

confidence: 99%

Neuro-ophthalmic manifestations of cancer: a narrative review

Janetos¹,

Volpe²,

Simon³

2022

Chin Clin Oncol

View full text Add to dashboard Cite

Background and Objective: Neuro-ophthalmic manifestations of cancer are vast and early recognition of a serious ocular condition due to either cancer or its therapy is important for both vision preservation as well as providing valuable treatment and prognostic information regarding the underlying malignancy. This review focuses on direct and indirect effects of cancer on the eye and its adnexa, hematologic malignancy, complications of traditional and novel oncologic therapies, and paraneoplastic syndromes as they relate to the eye as these disorders can lead to potentially devastating or irreversible vision loss.Methods: PubMed was searched primarily for the following topics: optic nerve infiltration, primary vitreoretinal lymphoma (PVRL), ocular paraneoplastic disorders, and ophthalmic complications of cancer therapeutics. Literature was selected based on historical significance and landmark studies (e.g., Cross et al.series of paraneoplastic optic neuritis patients; Chan's textbook on primary intraocular lymphoma) as well as publications published after 2000. References from select studies were additionally included. Given the sparsity of literature on many subjects, most publications were included during this time frame in our review.

show abstract

The impact of anticancer drugs on the ocular surface

Cited by 16 publications

References 96 publications

Incidence, Risk Factors and Complications of Ocular Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation

Incidence, Risk Factors and Complications of Ocular Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation

Subepithelial Corneal Deposits Associated with Exemestane

Neuro-ophthalmic manifestations of cancer: a narrative review

Contact Info

Product

Resources

About